Short Interest Alert: CANTABIO PHARMACEUTICALS INCORPORATED (OTCMKTS:CTBO) Shorts Decreased by 7.26% After Short Covering

November 30, 2016 - By Adrian Mccoy   ·   0 Comments

Short Interest Alert: CANTABIO PHARMACEUTICALS INCORPORATED (OTCMKTS:CTBO) Shorts Decreased by 7.26% After Short Covering

The stock of CANTABIO PHARMACEUTICALS INCORPORATED (OTCMKTS:CTBO) registered a decrease of 7.26% in short interest. CTBO’s total short interest was 11,500 shares in November as published by FINRA. Its down 7.26% from 12,400 shares, reported previously. With 37,800 shares average volume, it will take short sellers 0 days to cover their CTBO’s short positions. About 2,740 shares traded hands. Cantabio Pharmaceuticals Inc (OTCMKTS:CTBO) has risen 6.00% since October 31, 2016 and is uptrending. It has outperformed by 0.77% the S&P500.

Cantabio Pharmaceuticals Inc. is a preclinical stage biotechnology firm focusing on commercializing therapies and the intellectual property generated from its research and development activities for Parkinson’s disease , Alzheimer’s disease (AD) and other related neurodegenerative diseases. The company has a market cap of $7.90 million. The Company’s strategy integrates a detailed therapeutic focus, target family biophysics, and drug discovery technology and expertise into a drug discovery approach, which is currently identifying and developing small molecule pharmacological chaperones for clinical trials. It currently has negative earnings.

More recent Cantabio Pharmaceuticals Inc (OTCMKTS:CTBO) news were published by: Seekingalpha.com which released: “Cantabio Pharma: Is This Stock Worth Remembering?” on June 13, 2016. Also Globenewswire.com published the news titled: “Cantabio Pharmaceuticals to Present at 2016 Silicon Valley Bank Healthcare …” on September 19, 2016. Globenewswire.com‘s news article titled: “CANTABio and Gardedam Therapeutics complete Merger to Tackle Development of …” with publication date: December 21, 2015 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Adrian Mccoy


Readers Comments (0)





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>